Clinical Trial Update: Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria [Phase 1]

View source ↗

Summary

A Phase 1 study update reports completion of evaluating AK006 for safety, tolerability, pharmacokinetics, and immunogenicity in healthy participants and individ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• AK006

Snippet

Sponsor: Allakos Inc. | Conditions: Healthy Participants, Chronic Spontaneous Urticaria | Phase 1 | Status: COMPLETED